Radiotherapy (XRT) is a curative treatment option for prostate cancer (PCa). Recent XRT technologies allow higher dose therapy that lead to increased local control with less adjacent tissue damage. Additionally, receiving neo-adjuvant or adjuvant hormonotherapy (HT) during radiation therapy increases the curative effect. The aim of this paper is to review the current literature and guidelines on external beam radiation therapy for PCa. However, brachytherapy and radiosurgery, a recently evolving relatively new technology for the radiotherapeutic management of localized PCa, are beyond the scope of this paper.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814956 | PMC |
| http://dx.doi.org/10.4103/1008-682X.156857 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
External beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study.
BMC Cancer
January 2025
Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
Background: This paper describes the rationale and design of the RECOVER study. Currently, there is no consensus regarding the optimal treatment for high-risk, non-metastatic prostate cancer (PCa). The study primarily aims to evaluate and compare the impact of treatment with robot-assisted radical prostatectomy (RP) versus external beam radiation therapy (EBRT) with androgen deprivation therapy (ADT) for men with high-risk, non-metastatic PCa regarding health-related quality of life (HRQoL) and functional outcomes.
View Article and Find Full Text PDFRecurrent Poorly Differentiated Thyroid Cancer Successfully Treated With Radiation and Immunotherapy.
JCEM Case Rep
February 2025
Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX 77030, USA.
A 65-year-old patient presented with recurrent, locally advanced poorly differentiated thyroid cancer despite 2 neck surgeries, and with newly diagnosed brain and skull base metastases. He was treated with palliative stereotactic radiosurgery to the brain and skull base lesions. Thereafter, as no targetable genetic alteration was identified and antiangiogenic multikinase inhibitors were deemed at high risk of hemorrhagic complications, off-label systemic therapies were considered.
View Article and Find Full Text PDFEvaluation of charge summing correction in CdTe-based photon-counting detectors for breast CT: performance metrics and image quality.
J Med Imaging (Bellingham)
January 2025
U.S. Food and Drug Administration, Office of Science and Engineering Labs, Division of Imaging, Diagnostics, and Software Reliability, Silver Spring, Maryland, United States.
Purpose: We evaluate the impact of charge summing correction on a cadmium telluride (CdTe)-based photon-counting detector in breast computed tomography (CT).
Approach: We employ a custom-built laboratory benchtop system using the X-THOR FX30 0.75-mm CdTe detector (Varex Imaging, Salt Lake City, Utah, United States) with a pixel pitch of 0.
The value of magnetic resonance imaging in predicting vesicovaginal fistula in cervical cancer with bladder invasion treated with definitive chemoradiotherapy.
Gynecol Oncol
January 2025
Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address:
Objectives: To assess the predictive value of magnetic resonance imaging for vesicovaginal fistula development in cervical cancer patients with bladder invasion treated with definitive chemoradiotherapy.
Methods: A retrospective review was conducted of the medical records of 43 cervical cancer patients with bladder invasion between 1999 and 2015. Bladder invasion was confirmed through magnetic resonance imaging (scores ≥3) or cystoscopic findings, with or without biopsy.
Development of an in vivo ovarian cancer peritoneal carcinomatosis model for radioimmunotherapy testing.
Methods Cell Biol
January 2025
Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France. Electronic address:
Currently, Ovarian Cancer (OC) is the most lethal gynecological malignancy. In most patients, it progresses without clinical signs or symptoms, leading to a late diagnosis when it has already spread in the peritoneal cavity as peritoneal carcinomatosis (PC). To date, OC PC management is based on cytoreductive surgery to remove the macroscopic disease, followed by chemotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!